Showing results (41-50 of 406) with videos related to
Sort By:
Pageof 41
Monash Bioethics Review|August 13, 2025
Vaccine refusal in cancer patients at the French hospital: a normative re-analysis through a 'neopotterian theory of global bioethics'Henri-Corto Stoeklé, Sakina Sekkate, Jaafar Bennouna, et al.BMC Health Services Research|May 25, 2022
Cancer and COVID-19: ethical issues concerning the use of telemedicine during the pandemicLucas Huret, Henri-Corto Stoeklé, Asmahane Benmaziane, et al.BMJ Supportive & Palliative Care|April 23, 2021
The Supportive Care sCore (SCC): trigger alert validation study in solid tumoursMathilde Chastenet, Pierre-Antoine Laurain, Julia Salleron, et al.The Oncologist|February 25, 2020
Managing Hyperprogressive Disease in the Era of Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade: A Case Discussion and Review of the LiteratureMiruna Grecea, Aurélien Marabelle, Samy Ammari, et al.Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|July 11, 2006
[Sarcomatoid carcinoma with heterologous osteoid differentiation]Michaël Peyromaure, Philippe Beuzeboc, Dimitri Chekulaev, et al.Presse Medicale (Paris, France : 1983)|December 28, 2007
[Chemotherapy for prostate cancer]Jacques Medioni, Dimitri Dionysopoulos, Eugéniu Banu, et al.Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|April 22, 2003
[Testicular germ cell tumors: prognosis]Makram Miladi, Michaël Peyromaure, Julien Remi, et al.Urology|January 31, 2004
Concurrent chemoradiotherapy for clinical stage T2 bladder cancer: report of a single institutionMichaël Peyromaure, Jerôme Slama, Philippe Beuzeboc, et al.Bulletin Du Cancer|September 13, 2007
[New targeted therapies in hormone-refractory prostate cancer]Stéphane Oudard, Eugeniu Banu, Florian Scotte, et al.Pageof 41